Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Stage IV Melanoma
NCT00003509Phase 2Terminated
- Sponsor
- Burzynski Research Institute
- Start
- Mar 1996
- Primary completion
- Feb 2005
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in Malignant Melanoma (MM), sponsored by Burzynski Research Institute. Primary endpoint: Number of Participants With Objective Response at 5 months. Started Mar 1996; status: terminated.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00003509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003509.